131 I标记人源抗HBs Fab瘤内注射治疗荷人肝癌裸鼠的实验研究

目的　探讨13 1I标记人源抗乙肝表面抗原单克隆抗体Fab片段 (抗HBsFab)瘤内给药治疗荷人肝癌裸鼠移植瘤的合理性。方法　荷瘤裸鼠分为 5组 ,分别经瘤内注射13 1I 抗HBsFab、13 1I 无关Fab、13 1I、PBS及腹腔注射13 1I 抗HBsFab。 5d后每组各取 2只作组织分布测定 ,其余观察 3周 ,计算各组肿瘤生长抑制率。结果　瘤内注射13 1I 抗HBsFab组放射性计数瘤 /肝比值是腹腔注射组的 9倍 ,3周后前者肿瘤生长抑制率高于后者 ,分别为 62 .3%和 46.7%。结论　采用瘤内注射13 1I标记人源抗HBsFab导向治疗肝癌 ,具有低毒高效的治疗作用 ,临床实用价值大

The experimental study on the radioimmunotherapy of the hepatoma in nude mice model with intratumoral injection of 131 I-human anti-HBsAg Fab

Objective To study the therapeutic efficacy of radioimmunotherapy of 131 I human anti HBsAg Fab via different routes of administration. Methods The human hepatoma bearing nude mice were injected with 131 I human anti HBsAg Fab intratumorally(IT) and intra peritoneally (IP).Biodistribution was measured on the 5th day.The tumor growth inhibition rate was determined by measurement of tumor volume. Results In the IT treated mice,tumor uptake of 131 I human anti HBsAg Fab was four fold greater than in the IP treated mice,and normal organ uptake was half of that in the IP treated mice.At the 3rd week after the infusion,the tumor growth inhibition rate in IT treated mice was higher than that in the IP treated mice. Conclusions Intratumoral administration of 131 I human anti HBsAg Fab makes high level of radioactivity retained in tumor with significantly lower radioactivity retained in normal tissues,and provides a more effective regional therapy.